Early Diagnosis of Oral Cancer by Detecting p16 Hydroxymethylation

A Multicentral Prospective Study on Prediction of Malignant Progression of Oral Epithelial Dysplasia With p16 Hydroxymethylation

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02967120

Enrollment

265

Registered

2016-11-17

Start date

2014-01-31

Completion date

2018-01-31

Last updated

2017-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Epithelial Dysplasia

Brief summary

The purpose of this study is to verify the function of p16 hydroxymethylation diagnostic reagents in early diagnosis of oral cancer.

Detailed description

Background:Oral epithelial dysplasia (OED) is one of the common precancerous lesions among Chinese adults. To investigate the clinical predictive value of p16 hydroxymethylation diagnostic reagents in the early diagnosis of oral cancer, the investigators carried out the prospective multi-center double-blind cohort study. Methods:265 patients with histologically confirmed mild or moderate OED were included in the present study. After the bisulfite modification and tet assistant bisulfite modification, MethyLight and Methylation-specific PCR (MSP) assays were used to analyze p16 methylation and status in these patients. Building three follow-up queue by p16-methylated, p16-hydroxymethylation and p16-unmethylated. The Statistical analysis used SPSS16.0. All P-values were two-sided. P\<0.05 was considered to test for statistical significance difference.

Interventions

OTHERno intervention

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

25 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histopathological diagnosis of oral lesions meet the epithelial diagnostic criteria for mild to moderate grade OED; * No local area stimulate by residual root and crown, sharp cusp, poor restoration and biting cheek or lips; * Without the treatment history by laser , radiation or chemical; * Be able to Sign the informed consent;

Exclusion criteria

* Histopathological diagnosis of oral lesions do not meet the epithelium of mild to moderate dysplasia diagnostic criteria; histological diagnosis of severe grade OED or malignant disease; * Pregnancy or breast-feeding women; * Serious heart, lung, liver , kidney and other systemic diseases local area stimulate by residual root and crown, sharp cusp, poor restoration and biting cheek or lips; * OED treatment history by LASER, radiotherapy, or chemotherapy; * Tumor and psychiatric patients; * Patients are unable to cooperate;

Design outcomes

Primary

Measure	Time frame	Description
Cancer rate in patients with oral epithelial dysplasia containing or NOT containing p16 hydroxymethylation	from 3 months to 60 months	Among these cases, oral specimens from 24 patients were p16-hydroxymethylation, 54 patients were p16-methylation and 187 patients were p16-unmethylation. The cancer rate in the p16-hydroxymethylation patients during the followup period will be compared with that in the other two groups.

Secondary

Measure	Time frame
Disease free survival of patients with oral epithelial dysplasia containing or Not containing p16 hydroxymethylation	from 3 months and 36 months

Countries

China

Contacts

Primary ContactZhaojun Liu, PhD

liuzhaojun@bjmu.edu.cn86-010-88196721

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026